177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
| Autor: | Hofving, Tobias, Sandblom, Viktor, Arvidsson, Yvonne, Shubbar, Emman, Altiparmak, Gülay, Swanpalmer, John, Almobarak, Bilal, Elf, Anna-Karin, Johanson, Viktor, Elias, Erik, Kristiansson, Erik, Forssell-Aronsson, Eva, Nilsson, Ola |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
peptide receptor radionuclide therapy
Adult Aged 80 and over Male Mice Inbred BALB C Research ganetespib 177Lu-octreotate therapy Mice Nude Antineoplastic Agents Hsp90 inhibitor Lutetium Middle Aged Triazoles Octreotide Neuroendocrine Tumors Tumor Cells Cultured Animals Humans Female neuroendocrine tumours HSP90 Heat-Shock Proteins Radiopharmaceuticals Aged |
| Zdroj: | Endocrine-Related Cancer |
| ISSN: | 1479-6821 1351-0088 |
| Popis: | 177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolonging progression-free survival, but complete responses are still uncommon. The aim of this study was to improve the 177Lu-octreotate therapy by means of combination therapy. To identify radiosensitising inhibitors, two cell lines, GOT1 and P-STS, derived from small intestinal neuroendocrine tumours (SINETs), were screened with 1224 inhibitors alone or in combination with external radiation. The screening revealed that inhibitors of Hsp90 can potentiate the tumour cell-killing effect of radiation in a synergistic fashion (GOT1; false discovery rate |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|